Neogen Chemicals Foresees Battery Chemical Revenue Reaching INR 2,400–2,900 Crore By FY29

Market snapshot: Neogen Chemicals has outlined a major strategic blueprint for its battery materials subsidiary, Neogen Ionics, projecting a long-term revenue potential of ₹2,400 crore to ₹2,900 crore by FY29 at full capacity. The company has guided for ₹300 crore plus in battery chemical revenues for FY27, with the bulk expected in the second half of the year. Additionally, standalone FY27 revenue is expected to range between ₹950 crore and ₹1,050 crore, with the core business anticipated to cross ₹1,000 crore (as stated in the source alert; not independently verified).

Data Snapshot

• Long-term battery chemicals revenue potential is projected to reach ₹2,400 crore to ₹2,900 crore by FY29.
• The company expects battery chemical revenues (Neogen Ionics) of ₹300 crore plus in FY27, heavily back-loaded in H2.
• The aggregate project cost for Neogen Ionics' Dahej Phase 1 and Pakhajan Phase 2 projects stands at ₹1,795 crore.
• Target Return on Capital Employed (ROCE) for the battery materials business is set at 18% to 20% by FY29.

What's Changed

• Q1 FY27 consolidated revenue grew by 34% YoY to ₹250 crore from ₹187 crore in Q1 FY26.
• Q1 FY27 consolidated EBITDA increased by 53% YoY to ₹48 crore from ₹32 crore in Q1 FY26.
• Q1 FY27 consolidated PAT grew 67% YoY to ₹17 crore from ₹10 crore in Q1 FY26.

Key Takeaways

• Aggressive Battery Chemicals Pivot: Neogen is investing ₹1,795 crore across Dahej Phase 1 (₹428 crore) and Pakhajan Phase 2 (₹1,367 crore) to establish commercial-scale electrolyte and salt capacities.
• FY29 Revenue Potential: At optimum utilization, the battery division is projected to touch ₹2,400 crore to ₹2,900 crore in revenues by FY29, driven by 30 GWh of electrolyte and 40 GWh of salt capacity.
• Near-Term Horizon: Neogen Ionics is guided to achieve ₹300 crore plus in revenues for FY27, with a sequential quarterly ramp-up mostly materializing in the second half of the fiscal year.
• Profitability & Efficiency: Management is targeting a robust 18% to 20% ROCE on its revised battery materials CAPEX layout, leveraging Japanese technology partnerships for design and scale optimization.

SAHI Perspective

Neogen Chemicals' structural transition from a traditional bromine-based and inorganic lithium manufacturer to a specialized battery materials champion is highly strategic. While the substantial capex of ₹1,795 crore has temporarily bloated interest costs, the long-term revenue visibility of up to ₹2,900 crore by FY29 validates the execution roadmap. Additionally, their joint venture with Japan's Morita for a non-FEOC compliant LiPF6 supply chain provides a significant structural advantage in western markets, isolating them from Chinese geopolitical dependencies.

Market Implications

The commissioning of Pakhajan Phase 2 in H2 FY27 will position Neogen as one of India's earliest domestic suppliers of lithium electrolyte salts. This aligns perfectly with India's Advanced Chemistry Cell (ACC) PLI rollout, where cell manufacturers must meet local value-addition norms. The domestic chemical sector will see an import-substitution shift, reducing supply chain friction and pricing volatility for Indian gigafactories.

Trading Signals

Market Bias: Bullish

Strong consolidated Q1 FY27 revenue growth of 34% YoY and EBITDA growth of 53% highlight robust underlying demand. The scheduled commissioning of Dahej Phase 1 (February 2027) and Pakhajan Phase 2 (March 2027) will serve as major volume triggers.

Overweight: Specialty Chemicals, Lithium Battery Materials, EV Supply Chain

Underweight: Commodity Chemicals

Trigger Factors:

• Commissioning of the Dahej Phase 1 replacement plant by February 2027.
• Successful customer validation and pilot trials of Pakhajan electrolyte salts in H2 FY27.
• Further insurance settlements for the Dahej fire incident, which have already recovered ₹164 crore to date.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian specialty chemical sector is actively capitalizing on the global 'China+1' strategy and domestic EV mandates. Under the government's ₹18,100 crore battery PLI, cell manufacturers are scaling up gigafactories, translating to a projected domestic electrolyte demand of over 150,000 metric tons by 2030. Early movers like Neogen, with proven Japanese technology licensing, stand to capture substantial market share.

Key Risks to Watch

• Project Commissioning Timelines: Any delays in completing the ₹1,795 crore Dahej or Pakhajan expansions could drag on near-term revenue targets.
• Lithium Price Volatility: Underlying specialty chemical revenues remain sensitive to international lithium carbonate and hydroxide prices.
• Client Qualification Cycles: Battery cell manufacturers have long qualification windows, and commercial sales are dependent on final trial approvals.

Recent Developments

In Q1 FY27, Neogen Ionics recorded stellar growth, with revenues reaching ₹19 crore compared to ₹5 crore in Q1 FY26. Neogen also secured a recent insurance claim tranche of ₹15 crore in July 2026, bringing cumulative recoveries from the Dahej fire incident to ₹164 crore. Additionally, the specialized MUIS electrolyte plant trial runs at Pakhajan are progressing on schedule.

Closing Insight

Neogen Chemicals is transitioning from a traditional mid-sized chemical manufacturer to a frontrunner in India's green energy supply chain. While high interest and capex drag near-term margins, its technological moat and long-term agreements make it a highly compelling multi-year structural play.

High Performance Trading with SAHI.